SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
{1} Announces That Neramexane Did Not Demonstrate Statistical Significance In Recently Completed Phase III Trial In Patients With Moderate To Severe Alzheimer's Disease